Establishing a Th17 based mouse model for preclinical assessment of the toxicity of candidate microbicides

Chinese Medical Journal

Volumn 123, Issue 23, 2010, Pages 3381-3388

  Li, Liang Zhu ^a   Yang, Yu ^a   Yuan, Song Hua ^a   Wan, Yan Min ^a   Qiu, Chao ^b   Feng, Yan Ling ^a   Xu, Jian Qing ^a,b,c   Zhang, Xiao Yan ^a,b,c  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Hunman immunodeficiency virus 1; Inflammatory cytokine; Microbicide; Murine model; Nonoxynol 9

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; NONOXINOL 9; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; INFLAMMATION; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; TH17 CELL; UPREGULATION; VAGINAL LAVAGE;

ANIMALS; ANTI-INFECTIVE AGENTS; COST-BENEFIT ANALYSIS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LINEAR MODELS; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; NONOXYNOL; TH17 CELLS; VAGINA;

EID: 78649853626     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.23.002     Document Type: Article

References (32)

1. Ehrhardt AA, Sawires S, McGovern T, Peacock D, Weston M. Gender, empowerment, and health: what is it? How does it work? J Acquir Immune Defic Syndr 2009; 51 Suppl 3: s96-s105.
2. Cutler B, Justman J. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis 2008; 8: 685-697.
3. Li SW, Zhang XY, Li XX, Wang MJ, Li DL, Ruan YH, et al. Detection of recent HIV-1 infections among men who have sex with men in Beijing during 2005-2006. Chin Med J 2008; 121: 1105-1108.
4. A joint assessment of HIV/AIDS prevention, treatment and care in China, 2007. (Accessed December 1, 2009 at http://www.chinaaids.cn.)
5. The Ministry of Health of the People's Republic of China, 2009 Update on the HIV/AIDS epidemic in China. (Accessed December 2, 2009 at http://www.moh.gov.cn)
6. HIV/STI Prevention Research and Development: July 2009 Pipeline Update of Microbicide and PrEP Candidates. (Accessed July 2, 2009 at http://www.microbicide.org/galleries/clinical-trials/MicrobicidePipelineUpdate02July2009.pdf.)
7. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomized controlled trial. Lancet 2002; 360: 971-977.
8. Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Weir SS, Wong EL. A controlled trial of nonoxynol-9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 1998; 339: 504-510.
9. Hillier SL, Moench T, Shattock R, Black R, Reichelderfer P, Veronese F. In vitro and in vivo: the story of nonoxynol 9. J Acquir Immune Defic Syndr 2005; 39: 1-8.
10. Eckstein P, Jackson MC, Millman N, Sobrero AJ. Comparison of vaginal tolerance tests of spermicidal preparations in rabbits and monkeys. J Reprod Fertil 1969; 20: 85-93.
11. Krebs FC, Miller SR, Catalone BJ, Welsh PA, Malamud D, Howett MK, et al. Sodium dodecyl sulfate and C31G as microbicidal alternatives to nonoxynol-9: comparative sensitivity of primary human vaginal keratinocytes. Antimicrob Agents Chemother 2000; 44: 1954-1960.
12. Cummins JE Jr, Guarner J, Flowers L, Guenthner PC, Bartlett J, Morken T, et al. Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob Agents Chemother 2007; 51: 1770-1779.
13. Catalone BJ, Kish-Catalone TM, Budgeon LR, Neely EB, Ferguson M, Krebs FC, et al. Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides. Antimicrob Agents Chemother 2004; 48: 1837-1847.
14. Patton DL, Cosgrove Sweeney YT, Paul KJ. A summary of preclinical topical microbicide vaginal safety and chlamydial efficacy evaluations in a pigtailed macaque model. Sex Transm Dis 2008; 35: 889-897.
15. Yu RR, Cheng AT, Lagenaur LA, Huang W, Weiss DE, Treece J, et al. A Chinese rhesus macaque (Macaca mulatta) model for vaginal lactobacillus colonization and live microbicide development. J Med Primatol 2009; 38: 125-136.
16. Veazey RS. Microbicide safety/efficacy studies in animals: macaques and small animal models. Curr Opin HIV AIDS 2008; 3: 567-573.
17. Assays and models for microbicide research: the current inventory and possible implications. (Accessed July 15, 2007 at http://www.microbicide.org/galleries/conferences-digest/IAS2007.Poster.ModelsAssays.FINAL.AMD.15July07.pdf)
18. Galen BT, Martin AP, Hazrati E, Garin A, Guzman E, Wilson SS, et al. A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety. J Infect Dis 2007; 195: 1332-1339.
19. Achilles SL, Shete PB, Whaley KJ, Moench TR, Cone RA. Microbicide efficacy and toxicity tests in a mouse model for vaginal transmission of Chlamydia trachomatis. Sex Transm Dis 2002; 29: 655-664.
20. McGowan I, Elliott J, Cortina G, Tanner K, Siboliban C, Adler A, et al. Characterization of baseline intestinal mucosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056). J Acquir Immune Defic Syndr 2007; 46: 417-425.
21. Fichorova RN, Bajpai M, Chandra N, Hsiu JG, Spangler M, Ratnam V, et al. Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol Reprod 2004; 71: 761-769.
22. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6: 1133-1141.
23. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361: 888-898.
24. Kattah MG, Wong MT, Yocum MD, Utz PJ. Cytokines secreted in response to Toll-like receptor ligand stimulation modulate differentiation of human Th17 cells. Arthritis Rheum 2008; 58: 1619-1629.
25. Beer BE, Doncel GF, Krebs FC, Shattock RJ, Fletcher PS, Buckheit RW Jr, et al. In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob Agents Chemother 2006; 50: 713-723.
26. Vargas G, Shilagard T, Johnston R, Bell B, Stegall RL, Vincent K, et al. Use of high-resolution confocal imaging of the vaginal epithelial microstructure to detect microbicide toxicity. J Infect Dis 2009; 199: 1546-1552.
27. 3 after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102. J Acquir Immune Defic Syndr 2006; 42: 140-148.
28. Vogler MA, Teppler H, Gelman R, Valentine F, Lederman MM, Pomerantz RJ, et al. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248). J Acquir Immune Defic Syndr 2004; 36: 576-587.
29. Ruxrungtham K, Suwanagool S, Tavel JA, Chuenyam M, Kroon E, Ubolyam S, et al. A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand. AIDS 2000; 14: 2509-2513.
30. Alfano M, Poli G. The cytokine network in HIV infection. Curr Mol Med 2002; 2: 677-689.
31. Gayle HD, Hill GL. Global impact of human immuno- deficiency virus and AIDS. Clin Microb Rev 2001; 14: 327-335.
32. Shattock RJ, Moore JP. Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 2003; 1: 25-34.